PMID- 34924754
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 17
DP  - 2021
TI  - Relationship Among Homocysteine, Inflammation and Cognitive Impairment in 
      Patients with Acute Ischemic Stroke and Transient Ischemic Attack.
PG  - 3607-3616
LID - 10.2147/NDT.S333753 [doi]
AB  - PURPOSE: To investigate the associations among homocysteine (Hcy), inflammation 
      and cognitive impairment in patients with acute ischemic stroke (AIS) and 
      transient ischemic attack (TIA). PATIENTS AND METHODS: Patients included were 
      enrolled from a subgroup of China National Stroke Registry-III (CNSR-III). We 
      used a Chinese version of Montreal Cognitive Assessment (MoCA) to screen for 
      cognitive impairment. We used high-sensitivity C-reactive protein (hsCRP) level 
      to reflect the inflammatory status, which was assessed at baseline together with 
      Hcy concentration. The primary outcome was the incidence of post-stroke cognitive 
      impairment (PSCI) at 3 months after AIS and TIA. Multivariable logistic 
      regression analysis was used to evaluate the correlation between Hcy and hsCRP, 
      and their effects on cognition. RESULTS: We enrolled 1466 patients with a median 
      age of 62 (54-70) years old, including 895 (61.05%) patients with elevated Hcy 
      levels, 466 (31.79%) with increased hsCRP concentrations, and 755 (51.50%) with 
      PSCI. In the group of patients with hyperhomocysteinemia (HHcy), higher hsCRP 
      levels were related to cognitive impairment, whether or not adjusted for multiple 
      potential confounders (crude OR: 1.71,95% CI: 1.29-2.27, p < 0.01; adjusted OR: 
      1.42, 95% CI: 1.04-1.93, p = 0.03). No significant interactions for the impact on 
      PSCI were observed in subgroups stratified by age, sex or Trial of Org 10172 in 
      Acute Stroke Treatment (TOAST) classification (P interaction > 0.05 for all). 
      CONCLUSION: High inflammatory levels increase the risk of cognitive impairment in 
      HHcy patients after AIS and TIA.
CI  - (c) 2021 Cui et al.
FAU - Cui, Lingyun
AU  - Cui L
AUID- ORCID: 0000-0003-3712-4114
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, People's Republic of China.
FAU - Lu, Ping
AU  - Lu P
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, People's Republic of China.
FAU - Li, Shiyu
AU  - Li S
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, People's Republic of China.
FAU - Pan, YueSong
AU  - Pan Y
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
FAU - Wang, Mengxing
AU  - Wang M
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
FAU - Li, Zixiao
AU  - Li Z
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, People's Republic of China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
FAU - Liao, Xiaoling
AU  - Liao X
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, People's Republic of China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, People's Republic of China.
AD  - China National Clinical Research Center for Neurological Diseases, Beijing, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20211211
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC8674150
OTO - NOTNLM
OT  - cognitive function
OT  - homocysteine
OT  - inflammation
OT  - stroke
OT  - transient ischemic attack
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/12/21 06:00
MHDA- 2021/12/21 06:01
PMCR- 2021/12/11
CRDT- 2021/12/20 06:01
PHST- 2021/09/04 00:00 [received]
PHST- 2021/11/27 00:00 [accepted]
PHST- 2021/12/20 06:01 [entrez]
PHST- 2021/12/21 06:00 [pubmed]
PHST- 2021/12/21 06:01 [medline]
PHST- 2021/12/11 00:00 [pmc-release]
AID - 333753 [pii]
AID - 10.2147/NDT.S333753 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2021 Dec 11;17:3607-3616. doi: 10.2147/NDT.S333753. 
      eCollection 2021.